The addition of brentuximab vedotin to lenalidomide and rituximab extended survival among heavily pretreated patients with ...

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Seagen was a pioneer in the development of ADC drugs, and has successfully brought two to market – Adcetris (brentuximab vedotin) for various type of lymphoma and Padcev (enfortumab vedotin ...

Adding Seagen's four approved oncology drugs – Adcetris (brentuximab vedotin) for blood cancers, Padcev (enfortumab vedotin) for bladder cancer and cervical cancer therapy Tivdak (tisotumab ...

June 20, 2024 — Research scientists found that a 'one-two punch' of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to ...

NEW YORK, February 24, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at ...

Marlise R. Luskin, MD, MSCE, a member of the Adult Leukemia Program at Dana-Farber Cancer Institute, associate program director of the Dana-Farber/Mass General Brigham Hematology/Oncology Fellowship ...

RZ-001, an RNA substitution enzyme-based cancer gene therapy, has been granted FDA fast track designation for hepatocellular carcinoma (HCC), per a press release from Rznomics Inc. 1 This regulatory ...

Gwen Nichols, MD, discussed the impact of Medicaid reductions on patient care and how oncologists can advocate for accessible cancer treatment during these uncertain times. Medicaid reductions and ...